Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Milei Threatens Falkland Oil Firms With Sanctions 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
France Targets Shein, Temu With Fast-Fashion Fees 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
OpenAI Rejects Apple Trade Secret Theft Claims 
Add as a preferred source on Google
AUSTIN, Texas, March 07, 2018 -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer, are scheduled to participate in the 30th Annual ROTH Conference, taking place March 11-14 at the Ritz Carlton Hotel in Laguna Niguel, California.
Presentation Details
Date: Tuesday, March 13
Time: 3:30pm Pacific Time/6:30pm Eastern Time
Location: Blue – Salon 2
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
Jeremy Feffer
LifeSci Advisors LLC
Tel 212-915-2568
[email protected]
